| 证券代码：603669 | 证券简称：灵康药业 公告编号：2025-054 | | --- | --- | | 债券代码：113610 | 证券简称：灵康转债 | 灵康药业集团股份有限公司 关于向下修正"灵康转债"转股价格暨转股停复牌的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、可转换公司债券的基本情况 （一）经中国证券监督管理委员会证监许可[2020]2640 号文核准，灵康药业 集团股份有限公司（以下简称"灵康药业"或"本公司"）于 2020 年 12 月 1 日公 开发行了 525 万张可转换公司债券，每张面值 100 元，发行总额为 525,000,000 元，期限 6 年。 （二）经上海证券交易所自律监管决定书[2020]412 号文同意，公司发行的 525,000,000 元可转换公司债券于 2020 年 12 月 22 日起在上海证券交易所挂牌交 修正前的转股价格：8.00 元/股 修正后的转股价格：6.50 元/股 "灵康转债"本次转股价格修正实施日期：2025 年 8 月 1 日 "灵康转 ...

上海东方华银律师事务所 法律意见书 上海东方华银律师事务所 上海东方华银律师事务所 上海市虹桥路 1591 号虹桥迎宾馆 34 号楼 电话：(8621) 68769686 上海东方华银律师事务所 法律意见书 上海东方华银律师事务所 关于灵康药业集团股份有限公司 关于灵康药业集团股份有限公司 2025 年第一次临时股东大会 之 法律意见书 2025 年第一次临时股东大会之法律意见书 致：灵康药业集团股份有限公司 上海东方华银律师事务所（以下简称"本所"）接受灵康药业集团股份有限 公司（以下简称"贵司"或"公司"）委托，就贵司召开 2025 年第一次临时股 东大会的有关事宜，根据《中华人民共和国公司法》（以下简称《公司法》）、 《上市公司股东会规则》（以下简称《股东会规则》）等法律、法规和其他规范 性文件以及《灵康药业集团股份有限公司章程》（以下简称《公司章程》）的有 关规定，出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的本次股东大会的相关资 料，包括但不限于公司召开 2025 年第一次临时股东大会的通知、公司 2025 年第 一次临时股东大会的议程、议案及决议等文件资料，同时听取了公司董事会秘 ...

证券代码：603669 证券简称：灵康药业 公告编号：2025-053 灵康药业集团股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 7 月 30 日 (二)股东大会召开的地点：浙江省杭州市上城区民心路 100 号万银国际大厦 27 层，浙江灵康药业有限公司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 211 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 311,401,913 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 44.2620% | | 份总数的比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由公司董事会召集，由公司董事长陶灵萍女士主持。本次会议的召 集、召开、表决方式符合有 ...

Group 1 - The company is holding its first extraordinary general meeting of shareholders in 2025 on July 30 at 14:30 in Hangzhou, Zhejiang [1] - The agenda includes signing in, reviewing proposals, voting, announcing results, and waiting for online voting results [1][2] - The board of directors is proposing to lower the conversion price of "Lingkang Convertible Bonds" to support long-term stable development and optimize the capital structure [3] Group 2 - The board seeks authorization from the shareholders to handle matters related to the adjustment of the conversion price, including determining the new price and effective date [3] - The authorization is valid from the date of approval at the shareholders' meeting until the completion of the related work [3]

灵康药业集团股份有限公司 2025 年第一次临时股东大会会议资料 灵康药业集团股份有限公司 灵康药业集团股份有限公司 2025 年第一次临时股东大会会议资料 (603669) 二〇二五年七月 2025 年第一次临时股东大会会议资料目录 | 2025 | 年第一次临时股东大会会议议程 | 2 | | --- | --- | --- | | 2025 | 年第一次临时股东大会会议须知 | 4 | | 议案一：关于向下修正"灵康转债"转股价格的议案 | | 5 | 第 1 页 共 5 页 灵康药业集团股份有限公司 2025 年第一次临时股东大会会议资料 灵康药业集团股份有限公司 2025 年第一次临时股东大会会议议程 现场会议时间：2025 年 7 月 30 日 14 点 30 分 现场会议地点：浙江省杭州市上城区民心路 100 号万银国际大厦 27 层，浙江灵 康药业有限公司会议室 议程： 一、 签到、宣布会议开始 1、与会人员签到，领取会议资料；股东及股东代理人同时提交身份证明材 料（授权委托书、营业执照复印件、身份证复印件等）并领取《表决票》； 2、主持人宣布灵康药业集团股份有限公司 2025 年第一次临时股 ...

Core Viewpoint - The board of directors of Lingkang Pharmaceutical Group Co., Ltd. proposes to lower the conversion price of "Lingkang Convertible Bonds" due to the stock price being below 85% of the current conversion price for at least 15 out of the last 30 trading days [1][4]. Summary by Sections 1. Basic Information of Convertible Bonds - Lingkang Pharmaceutical issued 5.25 million convertible bonds on December 1, 2020, with a face value of 100 yuan each, totaling 525 million yuan [2]. - The bonds are traded under the name "Lingkang Convertible Bonds" with the code "113610" [2]. 2. Conversion Price Adjustment Terms and Trigger Conditions - The conversion price can be adjusted if the stock price is below the current conversion price for at least 15 out of 30 consecutive trading days [3]. - The initial conversion price was set at 8.81 yuan per share, with the latest adjustment bringing it down to 8.00 yuan per share [2]. 3. Procedures for Price Adjustment Proposal - The board meeting on July 14, 2025, approved the proposal to lower the conversion price and will submit it to the shareholders' meeting for approval [4]. - The adjusted conversion price must not be lower than the higher of the average stock price over the 20 trading days prior to the shareholders' meeting and the previous trading day's average [5].

Group 1 - The company expects a net profit attributable to shareholders of the parent company for the first half of 2025 to be between -39.5 million and -35 million yuan, with a net profit excluding non-recurring gains and losses estimated between -48.5 million and -44 million yuan [1][2] - The projected operating revenue for the first half of 2025 is estimated to be between 160 million and 200 million yuan, with the revenue from core business activities expected to be between 153.4 million and 160 million yuan [1][2] - The company reported a net profit attributable to shareholders of the parent company for the same period last year of -40.4 million yuan, with a net profit excluding non-recurring gains and losses of -54.4 million yuan [2] Group 2 - The primary reason for the expected loss is that the gross profit from sales is insufficient to cover the period expenses, leading to a loss for the current period [2] - The company has increased efforts in promoting products that have won centralized procurement bids and is leveraging its channel advantages to enhance market promotion of non-procurement products [2] - The company aims to expand its pharmaceutical distribution business to strengthen its overall scale [2]

Group 1 - The board of directors of Lingkang Pharmaceutical Group Co., Ltd. held its 33rd meeting on July 14, 2025, to discuss the downward adjustment of the conversion price of "Lingkang Convertible Bonds" [1][2] - The board proposed to authorize the board to handle matters related to the adjustment of the conversion price, including determining the new conversion price and effective date [1] - The meeting was attended by all 7 directors, and the resolution was deemed legal and effective [1][2] Group 2 - The proposal to adjust the conversion price requires approval at the company's first extraordinary general meeting of shareholders in 2025 [2]

Group 1 - The company will hold its shareholder meeting on July 30, 2025, at 14:30 in Hangzhou, Zhejiang Province [1][3] - The voting method for the meeting will combine on-site voting and online voting through the Shanghai Stock Exchange's network voting system [1][2] - The network voting will be available on the same day from 9:15 to 15:00, with specific trading time slots for the voting platform [1][3] Group 2 - The meeting will review non-cumulative voting proposals that have already been approved by the company's board [2][3] - There are no related shareholders that need to abstain from voting [2] - Shareholders must register to attend the meeting, with specific requirements for both corporate and individual shareholders [4][5] Group 3 - Shareholders holding multiple accounts can vote through any of their accounts, but repeated voting will be counted only once [3][4] - The company has provided detailed instructions for the voting process, including identity verification for first-time online voters [3][4] - The company has specified the necessary documentation for both corporate and individual shareholders to attend the meeting [5]

证券代码：603669 证券简称：灵康药业 公告编号：2025-050 灵康药业集团股份有限公司 关于董事会提议向下修正"灵康转债"转股价格的公 告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 截至 2025 年 7 月 14 日，灵康药业集团股份有限公司（以下简称"灵康 药业"或"公司"）股价已出现连续三十个交易日中至少有十五个交易日的收盘 价低于当期转股价格的 85%之情形，已触发"灵康转债"的转股价格向下修正条 款。 经公司第四届董事会第三十三次会议审议通过，公司董事会提议向下修 正"灵康转债"的转股价格。 本次向下修正"灵康转债"转股价格尚需提交公司股东大会审议。 一、可转换公司债券的基本情况 （一）经中国证券监督管理委员会证监许可[2020]2640 号文核准，灵康药 业集团股份有限公司（以下简称"灵康药业"或"本公司"）于 2020 年 12 月 1 日公开发行了 525 万张可转换公司债券，每张面值 100 元，发行总额为 525,000,000 元，期限 6 年。 （二）经上海证券交易 ...